Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Letetresgene autoleucel (Primary)
- Indications Haematological malignancies; Solid tumours; Synovial sarcoma
- Focus Adverse reactions
- Sponsors Adaptimmune; GlaxoSmithKline; GSK
- 22 Sep 2023 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 21 Jul 2020 Planned number of patients changed from 444 to 250.
- 22 Mar 2020 Planned number of patients changed from 200 to 444.